Cellebrite DI (CLBT) Current Deferred Revenue (2020 - 2026)

Cellebrite DI has reported Current Deferred Revenue for 7 years, with the latest figure at $263.3 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 15.92% year-over-year to $263.3 million in Q2 2026; TTM through Jun 2026 was $263.3 million, a 15.92% increase from a year earlier, with the FY2025 full-year figure at $277.6 million, up 5.86% from the prior year.
• Current Deferred Revenue was $263.3 million for Q2 2026 at Cellebrite DI, up from $255.1 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $277.6 million in Q4 2025, with the low at $117.8 million in Q1 2022.
• Average Current Deferred Revenue over 5 years is $201.2 million, with a median of $200.8 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue soared 34.06% in 2023, then gained 5.86% in 2025.
• Over 5 years, Current Deferred Revenue stood at $194.9 million in 2022, then climbed by 24.6% to $242.8 million in 2023, then rose by 7.99% to $262.2 million in 2024, then grew by 5.86% to $277.6 million in 2025, then retreated by 5.13% to $263.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $263.3 million (Q2 2026), $255.1 million (Q1 2026), and $277.6 million (Q4 2025), per Business Quant data.